Limited downside seen in Dishman Pharma: Baliga

Limited downside is seen in Dishman Pharma, says Ambareesh Baliga, Independent Analyst.

Baliga told CNBC-TV18, “Dishman Pharma, topline is more or less as per expectation but the bottomline in fact I was expecting close to about 18.25-18.30 but there, there is a disappointment but at the same time we have seen the stock cracking from these levels of Rs 120-122 which we had seen recently. From there it has come down to Rs 95. So I don’t see much of a downside because of the results from here.”
On Feb 11, Dishman Pharma closed at Rs 93.80, down Rs 4.80, or 4.87%.  It has touched an intraday high of Rs 102 and an intraday low of Rs 88.65.